News Details - novonordisk.com
WEB3 days ago · Novo Nordisk A/S: Monlunabant phase 2a trial in obesity successfully completed. Bagsværd, Denmark, 20 September 2024 – Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral cannabinoid receptor 1 (CB1) inverse agonist. Monlunabant, formerly INV-202, was part of the acquisition of Inversago Pharmaceuticals Inc. announced in ...
Novo Nordisk A/S: Monlunabant phase 2a trial in obesity …
WEB2 days ago · Bagsværd, Denmark, 20 September 2024 – Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral cannabinoid receptor 1 (CB1) inverse ...
Novo Nordisk's Monlunabant Data Drags Stocks Of Smaller Players
WEB2 days ago · In March, Novo Nordisk shared monlunabant update during its Capital Markets Day 2024. In Phase 1, monlunabant produced a statistically significant mean weight loss of 3.5 kg (3.3%) compared to 0.6 ...
Novo Nordisk Stock Declines After Headline Results From Mid …
WEB2 days ago · Friday, Novo Nordisk A/S (NYSE:NVO) announced headline results from a phase 2a clinical trial with monlunabant, a small-molecule oral cannabinoid receptor 1 (CB1) inverse agonist. Monlunabant ...
Novo Nordisk (NVO): Monlunabant phase 2a trial in obesity …
WEB2 days ago · NVO Hot Sheet. (Updated - September 20, 2024 8:49 AM EDT) Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral cannabinoid receptor ...
Novo Nordisk’s obesity newcomer monlunabant heads into …
WEB2 days ago · Novo Nordisk has now announced headline results from a Phase IIa trial with monlunabant investigating the efficacy and safety of a once-daily 10 mg, 20 mg and 50 mg dose compared to placebo on body weight after 16 weeks in 243 people with obesity and metabolic syndrome. People were equally randomized among the four treatment arms.
Novo Nordisk shares drop nearly 5% on disappointing obesity pill …
WEB2 days ago · Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental obesity pill monlunabant came in below market expectations.
Novo Nordisk Slips On Phase 2a Clinical Trial Result With Monlunabant
WEB2 days ago · Friday, shares of Novo Nordisk A/S are sliding following the announcement of safety results of phase 2a clinical trial of Monlunabant compared to placebo in patients with obesity and metabolic syndrome.Monlunabant, formerly INV-202, is a small molecule oral cannabinoid receptor 1 or CB1 inverse agonist. The trial investigated efficacy and safety, and post 16 weeks, people treated with a once ...
Novo Nordisk's experimental weight loss pill has some ... - Yahoo
WEB2 days ago · Novo Nordisk stock fell nearly 6% during Friday morning trading after it posted the results. The Danish pharma giant tested monlunabant, a drug it acquired in 2023 with its $1 billion purchase of ...
Novo Nordisk A/S: Monlunabant phase 2a trial in obesity …
WEB2 days ago · Bagsværd, Denmark, 20 September 2024 – Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral cannabinoid receptor 1 (CB1) inverse agonist. Monlunabant, formerly INV-202, was part of the acquisition of Inversago Pharmaceuticals Inc. announced in August 2023 [Link].The trial investigated the efficacy and safety of a once-daily 10 ...
- Some results have been removed